Pamine® 2.5 mg/Pamine® Forte 5 mg Tablets
Pamine® 2.5 mg/Pamine® Forte 5 mg Tablets contain methscopolamine bromide, an anticholinergic agent.
Pamine (methscopolamine cation) is indicated for the following:
Adjunctive therapy for the treatment of peptic ulcer.
METHSCOPOLAMINE BROMIDE HAS NOT BEEN SHOWN TO BE EFFECTIVE IN CONTRIBUTING TO THE HEALING OF PEPTIC ULCER, DECREASING THE RATE OF RECURRENCE OR PREVENTING COMPLICATIONS.
Media Articles Related to Pamine (Methscopolamine)
Impulse control increased by dopamine replacement in early Parkinson's
Source: Anxiety / Stress News From Medical News Today [2014.08.19]
New Penn Medicine research shows that neuropsychiatric symptoms such as depression, anxiety and fatigue are more common in newly diagnosed Parkinson's disease (PD) patients compared to the general...
Dopamine release from ventral tegmental area may help speed emergence from anesthesia, avoid complications
Source: Pain / Anesthetics News From Medical News Today [2014.07.31]
Stimulating one of two dopamine-producing regions in the brain was able to arouse animals receiving general anesthesia with either isoflurane or propofol.
Supercomputer used to study a common link between addiction and neurological disease
Source: ADHD News From Medical News Today [2014.07.25]
Recent published research in the Journal of Clinical Investigation demonstrates how changes in dopamine signaling and dopamine transporter function are linked to neurological and psychiatric...
Epigenetic tie to neuropsychiatric disorders
Source: Schizophrenia News From Medical News Today [2014.07.24]
Flawed dopamine signaling linked to mass alteration of gene activity in prefrontal cortexDysfunction in dopamine signaling profoundly changes the activity level of about 2,000 genes in the...
Source: MedicineNet Antiemetics Specialty [2014.07.17]
Title: Peptic Ulcer
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 7/17/2014 12:00:00 AM
Published Studies Related to Pamine (Methscopolamine)
Methscopolamine bromide blocks hypothalamic-stimulated release of growth hormone in ewes. [1997.05]
Twenty-five nonlactating ewes were used to test the hypothesis that methscopolamine bromide (MB) blocks secretion of growth hormone (GH) by affecting hypothalamic rather than pituitary mechanisms. Ewes were randomly assigned to receive a s.c...
The muscarine antagonist methscopolamine and the NMDA antagonist AP-5 injected unilaterally into the nucleus accumbens cause mice to rotate in opposite directions. 
Previously, we have reported that the NMDA antagonist AP-5, injected unilaterally into the nucleus accumbens of mice, induces ipsilateral rotation in monoaminergically intact mice, but contralateral rotation in monoamine-depleted animals. In this paper we report that the muscarine antagonist methscopolamine, injected unilaterally into the nucleus accumbens, induced predominantly contralateral rotation in monoaminergically intact mice...
Dorsal striatal mechanisms involved in the dopamine D2 receptor-mediated potentiation of apomorphine-induced jaw movements. [1994.01.24]
The role of dorsal striatal mechanisms in the regulation of apomorphine-induced jaw movements was studied. Jaw movements induced by apomorphine (0.2 mg/kg i.v.) were potentiated by quinpirole (10 micrograms/0.2 microliter) injected into the dorsal part of the striatum 10 min before apomorphine...
Seizure promotion by D1 agonists does not correlate with other dopaminergic properties. 
A range of D1 receptor agonists were tested for their ability to facilitate limbic motor seizures induced by a subthreshold dose of the chemoconvulsant pilocarpine (100 mg/kg IP) in mice. ED50 values (mumol/kg) were calculated from log dose-probit analyses, giving relative proconvulsant potencies of SKF 82958 > CY 208-243 > SKF 77434 = SKF 75670 = SKF 80723 > SKF 38393...